Cytodyn Inc (CYDY)

[Rockydoxie]

"The CYDY press releases for their NASH results come across like they're written by someone with no medical/statistical experience whatsoever. The PRs are vague to the extent that they are misleading (probably on purpose)".

"Madrigal attacking GALT makes no sense. Madrigal's drug is in Phase III for NASH compared to Belapectin which is in Phase III for NASH cirrhosis. Look at the protocols: different baseline values, and different primary endpoints. But here is a tip for the Madrigal pumpers, please go to the CYDY board, where the rogue CEO is misleading investors regarding their NASH data. The misled retail investors are anxiously awaiting the results of Leronlimab's 700 mg dose. They presented data on the 350 mg, and the way it was reported was highly suspect."

The above comments (in quotes) were from the GALT stock msg. board and happened to mention CYDY.

Can anyone make an unbiased comment on the above? I've owned GALT for years and they're in the NASH space (for cirrhosis) and the space is difficult for approval. I was always suspicious of CYDY w/ the NASH application as many companies have been in the space for a long time w/o successful (to date) results.

I'm a long holder of CYDY. This is my first post. I don't pump or bash.

TIA